Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
BMS-820132 is an investigational new drug being developed by BMS for treating Type 2
diabetes. The purpose of this study is to test the safety/tolerability (potential side
effects) of single doses of the investigational new drug, as well as the amount of study drug
in the blood, in subjects with type 2 diabetes.